1	
2	
3	
4	Perceptions of access to harm reduction services during the COVID-19 pandemic
5	among people who inject drugs in Chicago
6	
7	
8	Kathleen Kristensen <sup>1*¶</sup> , Basmattee Boodram <sup>1¶</sup> , Wendy Avila <sup>1</sup> , Juliet Pineros <sup>1</sup> , Carl
9	Latkin <sup>2</sup> , Mary-Ellen Mackesy-Amiti <sup>1</sup>
10	
11	
12	
13 14 15 16 17 18 19 20 21	<sup>1</sup> Division of Community Health Sciences, University of Illinois Chicago School of Public Health, Chicago, Illinois, United States of America <sup>2</sup> Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
22	* Corresponding author
23	E-mail: <u>kkrist3@uic.edu</u> (KK)
24	
25	<sup>¶</sup> These authors contributed equally to this work.
26	
27 28	

# 29 ABSTRACT

30	Background. The COVID-19 pandemic amplified the risk environment for people who
31	inject drugs (PWID), making continued access to harm reduction services imperative.
32	Research has shown that some harm reduction service providers were able to continue
33	to provide services throughout the pandemic. Most of these studies, however, focused
34	on staff perspectives, not those of PWID. Our study examines changes in perceptions of
35	access to harm reduction services among PWID participating in a longitudinal study
36	conducted through the University of Illinois-Chicago's Community Outreach Intervention
37	Project field sites during the COVID-19 pandemic.
38	
39	Methods. Responses to a COVID-19 module added to the parent study survey that
40	assessed the impact of COVID-19 on PWID participating in an ongoing longitudinal
41	study were analyzed to understand how study participants' self-reported access to harm
42	reduction services changed throughout the pandemic. Mixed effects logistic regression
43	was used to examine difficulty in syringe access as an outcome of COVID-19 phase.
44	
45	Results. Most participants reported that access to syringes and naloxone remained the
46	same as prior to the pandemic. Participants had significantly higher odds of reporting
47	difficulty in accessing syringes earlier in the pandemic.
48	
49	Conclusions. The lack of perceived changes in harm reduction access by PWID and the
50	decrease in those reporting difficulty accessing syringes as the pandemic progressed
51	suggests the efficacy of adaptations to harm reduction service provision (e.g., window

- 52 and mobile service) during the pandemic. Further research is needed to understand
- 53 how the COVID-19 pandemic may have impacted PWIDs' engagement with harm
- 54 reduction services.

## 56 **INTRODUCTION**

The COVID-19 pandemic has disproportionately affected vulnerable populations, 57 including people who use drugs (PWUD) (1). Compared to people without a history of 58 59 substance use. PWUD are at increased risk for contracting and experiencing severe 60 outcomes from COVID-19 (e.g., hospitalizations and mortality), particularly if they have 61 a history of underlying health conditions including cardiovascular disease, type 2 62 diabetes, obesity, or cancer (1). Among PWUD, people who inject drugs (PWID) are at 63 a heightened risk of exposure to COVID-19 for two primary reasons: complex medical 64 comorbidities and social risk factors. Complex medical comorbidities include lung diseases such as asthma, immunodeficiencies from human immunodeficiency virus 65 (HIV) or co-infections such as tuberculosis or viral hepatitis, and cardiovascular 66 conditions such as hypertension. Each of these comorbidities are confirmed risk factors 67 for developing severe COVID-19 (2,3). Along with complex medical comorbidities, 68 69 vulnerability of PWID is further augmented by social factors such as homelessness. 70 incarceration, poverty, and limited access to healthcare due to drug use stigma and discrimination (4–10). Collectively, these risk factors are compounded by economic 71 72 hardships exacerbated by the COVID-19 pandemic, including food insecurity, housing 73 insecurity, and substandard sanitation conditions (3,5,11,12). For these and other 74 reasons, research specific to COVID-19 suggests that the pandemic escalated isolation, 75 loss of social support, and mental health decline among PWID (5,13). Compliance with public health recommendations such as physical distancing was challenging for PWID, 76 77 particularly those living in public spaces, shelters, and hostels (14). Additionally, 78 accessibility to crucial services such as social work, counseling, HIV and hepatitis C

(HCV) testing, harm reduction services, and inpatient drug treatment programs was
significantly reduced (5,13).

Harm reduction services, including syringe services programs (SSPs), safe 81 injection sites (SIFs), and naloxone distribution provide significant individual and public 82 83 health benefits, including preventing deaths from overdoses and preventing 84 transmission of bloodborne infections such as HIV and HCV among PWUD and their 85 networks. These services reduce emergency department visits and costly healthcare 86 services and may provide or facilitate linkage to substance use treatment (e.g., medication for opioid use disorder) (15). Moreover, these services may reduce stigma 87 associated with drug use, affect social norms among networks, and improve access to 88 89 essential resources (e.g., housing assistance, food banks, legal aid, mental health services, and employment services) (16–18). In some cases, COVID-19 mitigation 90 strategies contributed to making SSPs and medications for opioid use disorder (MOUD) 91 92 treatment more accessible by expanding mobile outreach, delivering equipment via 93 mail, relaxing syringe exchange policies, and loosening regulations on telemedicine (19,20). Other COVID-19 mitigation strategies such as social distancing and program 94 95 resource restrictions (e.g., staff, supply, financial) led to reduced access to harm reduction services, particularly SSPs, resulting in fewer opportunities for HIV testing, 96 97 HIV counseling, and obtaining sterile injection supplies. Since SSPs also provide a vital 98 location for social interaction and social support, the disruption of service modality (e.g., decreasing hours of operation, number of staff, and face-to-face interactions) has led to 99 100 increased feelings of isolation among PWID (19). These findings have been identified

101 across a range of locations, including 27 SSPs spread across the Northeast, Midwest,

102 South, and Western regions of the United States (19).

103 While existing research offers valuable insights into harm reduction service access during the pandemic, these studies largely focus on the perspectives of service 104 105 providers (19–21). Furthermore, the limited data reported directly by PWID are currently 106 confined to single regions of the country, such as New York (5), and further analysis is 107 necessary to determine if the conclusions are consistent in other regions as COVID-19 108 policies varied greatly by location. The present study aims to examine the impact of the COVID-19 pandemic on access to harm reduction services by exploring PWIDs' 109 perceptions of changes in access to these services over the course of the pandemic in 110 111 metropolitan Chicago, Illinois.

112

#### 113 MATERIAL AND METHODS

114 **Study setting.** We use data from an ongoing longitudinal study of PWID in metropolitan Chicago that included a COVID-19 specific module in the parent study 115 survey. The study was conducted at Community Outreach Intervention Projects (COIP), 116 117 a center within the School of Public Health at the University of Illinois at Chicago that 118 provides harm reduction services, including SSP, naloxone, HIV and HCV counseling 119 and testing, linkage to MOUD, and case management services to PWID and their 120 partners in the Chicago metropolitan area (includes the city of Chicago and its surrounding suburbs that span 16 counties in northeast Illinois, southeast Wisconsin, 121 122 and northwest Indiana.) The study was approved by the University of Illinois Chicago's 123 Institutional Review Board (Protocol #2017-0388).

124 COVID-19 Ordinance. In Illinois, where the study was conducted, a stay-athome ordinance was issued on March 20<sup>th</sup>, 2020, requiring non-essential workers to 125 126 stay at home and non-essential businesses to close. This directive prompted 127 community-based programs such as COIP, which provides critical treatment and harm 128 reduction services to PWID, to modify operations by reducing hours and limiting face-to-129 face contact. COIP staff continually worked throughout the COVID-19 pandemic within 130 compliance of the state and city ordinances. For example, harm reduction staff wore 131 personal protection gear (e.g. masks, googles, shields, gloves) and interacted with 132 clients through separation barriers to minimize interruptions to essential harm reduction services they provide to PWID in Chicago. On March 10<sup>th</sup>, 2020, COIP temporarily 133 134 reduced public access to essential services (e.g., specialized HIV care, SSP), 135 eliminating two of four sites and reducing hours of operation at open sites by approximately 50%. In May 2020, both COIP sites transitioned to a hybrid model of in-136 137 person and remote operations and gradually restored mobile services and full staffing at 138 all sites by June 2021, marking a return to pre-pandemic operations. The effects of these changes on the accessibility of services for PWID in metropolitan Chicago have 139 140 yet to be explored during this period, and to our knowledge, no prior study has 141 examined PWID's perception of access to harm reduction services during the 142 pandemic.

Sample and Recruitment. The present study uses data from a longitudinal
 COVID-19 survey initiated during the pandemic as a supplementary component to an
 ongoing longitudinal network and geographic study of young (aged 18-30) PWID and
 their injection, sexual, and social support network members in Chicago and the

147 surrounding suburbs (22). To be eligible, the primary participant (i.e., egos) had to (i) be 148 between ages of 18-30 years old, (ii) have injected drugs at least once in the past 149 month, (iii) proficiently speak English, and (iv) have resided in the city of Chicago or 150 surrounding suburbs during the past 12 months. Egos were asked to recruit up to five 151 members of their injection networks (i.e., alters); alters were eligible for the study if they 152 were (i) at least 18 years old, (ii) proficiently spoke English, (iii) resided in the city of 153 Chicago or surrounding suburbs during the past 12 months, and (iv) were referred to the 154 study by an ego. Egos and enrolled alters were followed every 6 months for up to 36 155 months to collect sociodemographic, network, geographic, and biologic (HIV/HCV 156 testing) data. A more detailed description of the methods for the parent study is outlined 157 in (22).

Participants (egos and alters) completing baseline or follow-up for the parent study were additionally asked to complete a survey on COVID-19 specific questions. These questions explored the effects of the COVID-19 pandemic on PWID, examining its implications on socioeconomic status, housing, injection drug use (IDU) behaviors and practices, and access to treatment and services.

We use baseline demographic data from the parent study as well as baseline and follow-up data from the COVID-19 survey. We used city level COVID-19 mitigation strategies as well as COIP's service changes during the pandemic to inform a descriptive analysis of study participants' perceptions of the accessibility of syringes and naloxone at different points in the pandemic.

168Data Collection. The COVID-19 survey was included in the parent study survey169from May 2020-December 2022. Ego participants were given the opportunity to retake

170 the COVID-19 survey at each remaining 6-month follow-up visit of the parent study, 171 while alters participated once. Participants were recruited from the COIP field site located on the West side of Chicago. COIP provides services including syringe 172 173 exchange, substance use counseling, and HCV and HIV testing and counseling as well 174 as conducting research with PWID. The field sites are located in Chicago 175 neighborhoods with high HIV, HCV, sexually transmitted infection incidence rates, and 176 drug-related arrests (12). Informed consent was obtained from all study participants 177 prior to data collection. 178 Measures. The present study examines demographic measures from the baseline responses to the Alter-ego parent study survey in addition to measures from 179 180 the COVID-19 sub-study of drug use behaviors, perceptions of drug use risk during the

181 COVID-19 pandemic, and perceptions of access to harm reduction services during the

182 COVID-19 pandemic. All responses are self-reported.

183 *Demographics.* Demographic characteristics were taken from the baseline parent 184 study survey responses and included age, gender, and race/ethnicity. Race/ethnicity 185 was categorized as non-Hispanic white, non-Hispanic Black, Hispanic, and mixed 186 race/other. Gender was reported using three categories—male, female, transgender; for 187 the purposes of analysis, this measure was dichotomized into the categories of male 188 and non-male.

*Drug Use Behaviors during COVID-19.* Drug use behaviors as assessed in the COVID-19 survey were examined. Participants were asked to report if they were currently using drugs (*yes/no*) or currently injecting drugs (yes/no) Participants were also asked if their injection frequency had changed as a result of COVID-19 (*decreased* 

*a lot, decreased somewhat, decreased a little, stayed the same, increased a little, increased somewhat, increased a lot*). and if their use of new, sterile syringes had
changed (*decreased a lot, decreased somewhat, decreased a little, stayed the same, increased a little, increased somewhat, increased a lot*). For analysis, injection
frequency was operationalized to indicate if injection frequency increased as a result of
the pandemic (*yes/no*), and sterile syringe use was operationalized to indicate if sterile
syringe use increased as a result of the pandemic (*yes/no*).

200 Perceptions of Drug Use Risk during COVID-19. Two questions in the COVID-19 201 survey addressed participants' perceptions of risk related to their drug use. Participants 202 were asked if, since the onset of the COVID-19 pandemic, people are more likely to 203 share syringes (more likely, neither more nor less likely, less likely). Participants were 204 also asked if the COVID-19 pandemic has changed the degree to which they are 205 concerned about overdose (decreased a lot, decreased somewhat, decreased a little, 206 stayed the same, increased a little, increased somewhat, increased a lot). For analysis, 207 syringe sharing was operationalized to indicate if participants thought individuals were 208 more likely to share syringes (yes/no), and concern about overdose as a result of 209 COVID-19 was operationalized to indicate if concern increased (yes/no).

210 *Perceptions of Access to Harm Reduction Services.* Participants' perceptions of 211 access to harm reduction services (e.g., sterile syringes, naloxone) as reported in the 212 COVID-19 survey were assessed. Regarding sterile syringe access, participants were 213 asked how their access to syringes now compares to their access prior to the onset of 214 the COVID-19 pandemic (*access is less difficult now, access is about the same, access* 215 *is more difficult now*). For analysis, syringe access was operationalized to indicate if

participants perceive syringe access as more difficult than prior to the pandemic
(*yes/no*). Participants were also asked if their source for obtaining new syringes has
changed since the onset of the COVID-19 pandemic (*yes/no*). Regarding naloxone
access, participants were asked if their access to naloxone has changed since the
onset of the COVID-19 pandemic (*yes/no*). Additionally, participants were asked if they
were aware of online sources of Narcan/naloxone and harm reduction supplies (*yes/no*).

222

### 223 Statistical Analysis.

Analyses for this study were conducted in SPSS version 28.0.1 and Stata 18.0. Prior to conducting descriptive analyses, we compared the respondents of the parent study baseline survey enrolled prior to the onset of the pandemic to those enrolled after the pandemic began to ascertain if there were any significant differences in their demographic characteristics, drug use, injection behaviors, or harm reduction usage profiles and found none.

230 Descriptive analysis of baseline COVID-19 survey participants (N=182) was then conducted. For categorical variables, response frequencies were calculated, and for 231 232 continuous variables the mean and standard deviation were calculated. For variables 233 that were only relevant to participants who reported engaging in IDU at the time of the 234 survey, frequency percentages were based on the subset of individuals who responded 235 "yes" to the guestion "Are you currently injecting drugs" (N=149). For variables that were 236 only relevant to participants currently using drugs, but not specifically injection drug use, 237 frequency percentages were based on the subset of individuals who responded "yes" to 238 the question "Are you currently using drugs" (N=159).

239 Next, baseline responses across Chicago COVID-19 phases were compared 240 using Chi-square and Fisher exact tests for all variables except age, which used 241 independent sample t-tests to compare means. This analysis was conducted to 242 determine if participant responses to measures of interest changed based on when 243 during the COVID-19 pandemic their survey was conducted. Chicago COVID-19 phases 244 were identified using the dates from press releases from the City of Chicago starting in 245 March of 2020 and ending in March of 2022. Four major phases of the COVID-19 policy 246 in Chicago were identified, as displayed in Figure 1. For the purposes of analysis, 247 phases 1 and 2 and phases 3 and 4 were combined to create a pre-vaccine stage (stage 1) and a post-vaccine phase (stage 2). These phases were combined for 248 249 analysis because i) phases 1 and 4 were significantly shorter periods of time than 250 phases 2 and 3 and creating two phases resulted in two more equal time periods, and ii) 251 there were many fewer responses to the COVID-19 survey during phase 1 (N=18) and 252 phase 4 (N=10). All measures were then compared between the pre-vaccine (N=96) 253 and post-vaccine (N=86) phases using Chi-square and Fisher exact tests and 254 independent sample t-tests.

255

256 Figure 1: Chicago COVID-19 Mitigation Policy Timeline.

257

Mixed effects logistic regression with random subject intercepts was used to further examine syringe access difficulty in repeated assessments over time as predicted by COVID-19 phase. In addition to COVID-19 phase, other potential covariates were explored using Chi-square and Fisher exact tests and independent

- sample t-tests to compare frequencies and means by perceived syringe access difficulty
- 263 for baseline responses. Cluster robust variance estimators were used to estimate
- standard errors and 95% confidence intervals.
- 265
- 266 **RESULTS**

### 267 Baseline Descriptive Analyses

- Table 1 displays the results of the descriptive analysis of baseline responses to
- the COVID-19 survey as well as the results of the comparison of responses by COVID-
- 19 phase. The sample was primarily male (70.6%) and non-Hispanic white (57.6%) with
- a mean age of initiation into parent study at 28.1 years old. Most of the sample reported
- currently injecting drugs (81.9%), with significantly (p=0.011) more participants doing so
- post-vaccine availability (phase 2) (89.5%) than pre-vaccine (phase 1) (75%). A
- sizeable proportion (32.2%) also reported increasing injection frequency to some
- 275 degree, though not statistically significant.
- 276

277	Table 1: Description of Baseline Survey Results and Comparison of COVID-19 Phase 1
278	and Phase 2 Survey Results. (N=182)

Variable	Responses	Frequency (%)	Pre-Vaccine Frequency (%)	Post- Vaccine Frequency (%)	p-value <sup>t</sup>
Demographics		-	-	-	
Age	Mean (S.d)	28.08 (5.29)	27.51 (4.59)	28.77 (5.97)	.116
Gender	Male	125 (70.6%)	67 (69.8%)	58 (71.6%)	.792
	Not Male	52 (29.4%)	29 (30.2%)	23 (28.4%)	
Race/ethnicity	White	102 (57.6%)	58 (60.4%)	44 (54.3%)	.628
	Black	11 (6.2%)	7 (7.3%)	4 (4.9%)	
	Hispanic	53 (29.9%)	25 (26.0%)	28 (34.6%)	
	Mixed/Other	11 (6.2%)	6 (6.3%)	5 (6.2%5)	
Currently Using Drugs	Yes	159 (87.4%)	79 (82.3%)	80 (93.0%)	.030

	No	23 (12.6%)	17 (17.7%)	6 (7.0%)	
Currently Injecting					
Drugs	Yes	149 (81.9%)	72 (75.0%)	77 (89.5%)	.011
	No	33 (18.1%)	24 (25.0%)	9 (10.5%)	
Increased sterile					
syringe use (N=149)	Yes	26 (17.34%)	8 (11.1%)	18 (23.4%)	.049
	No	123 (82.6%)	64 (88.9%)	59 (76.6%)	
Increased injection					
frequency (N=149)	Yes	48 (32.2%)	18 (25.0%)	30 (39.0%)	.068
	No	101 (67.8%)	54 (75.0%)	47 (61.0%)	
People more likely to					
(N=149)	Yes	29 (22.5%)	15 (23.4%)	14 (21.5%)	.796
	No	100 (77 5%)	49 (76 6%)	51 (78 5%)	
Increased concern		100 (11.070)	40 (10.070)	01 (70.070)	
about overdose	Yes	26 (16.6%)	11 (14.3%)	15 (18.8%)	.452
Increased syringe					
access difficulty					
(N=149)	Yes	40 (27.6%)	26 (36.6%)	14 (18.9%)	.017
	No	105 (72.4%)	45 (63.4%)	60 (81.1%)	
Source for obtaining					
new syringes					
changed (N=149)	Yes	23 (15.4%)	12 (16.7%)	11 (14.3%)	.688
	No	126 (84.6%)	60 (83.3%)	66 (85.7%)	
Access to Narcan				- (0.00()	
changed (N=159)	Yes	18 (11.4%)	11 (14.1%)	7 (8.8%)	.290
	No	140 (88.6%)	67 (85.9%)	73 (91.3%)	
Aware of online					
sources of Narcan		400 (07 00()		40 (00 00()	001
(N=159)	INO	108 (67.9%)	60 (75.9%)	48 (60.0%)	.031
	Yes	51 (32.1%)	19 (24.1%)	32 (40.0%)	

279

9 <sup>t</sup>p-values are the results of Chi-square tests for categorial variables, Fisher exact tests for categorial

variables with expected counts less than five, and independent sample t-tests for continuous variables.

282

Sterile syringe use did significantly change between phases, with more

participants reporting increased sterile syringe use post-vaccine (23.4%) than pre-

vaccine (11.1%). Most participants reported that they were not more likely (77.5%) to

share syringes since the onset of the pandemic. Additionally, most (83.4%) participants

did not report concern about overdose increasing compared to prior to the pandemic.

287 Most participants (84.6%) reported their syringe source location(s) to be unchanged and

access to syringes during the COVID-19 pandemic (72.4%) to not be more difficult.

However, there was a significant difference between phase 1 and 2 (p=.017); 18% more participants reported increased difficulty in syringe access in phase 1 of the pandemic than in phase 2.

292

# 293 Mixed Effects Logistic Regression

- Table 2 displays the results of exploratory analysis of potential predictors of
- syringe access difficulty using baseline data. Syringe access difficulty was significantly
- different across COVID-19 phases (p=.017). Syringe access difficulty was also
- significantly related to perceiving people as more likely to share syringes (p<.001).

Additionally, a change in the source for obtaining new syringes was significantly

- associated with increased syringe access difficulty (p<.001). Age, race/ethnicity, and
- 300 gender were not significantly associated with increased syringe access difficulty.
- 301

Table 2: Baseline Comparison of Potential Predictors of Perceived Syringe Access
 Difficulty (N=149)

		Increased Syringe Access		
		Yes	No	
Variable	Responses	Freq. (%)	Freq. (%)	p-value <sup>t</sup>
Post-Vaccine Phase	Yes	14 (35.0%)	60 (57.1%)	.017
	No	26 (65.0%)	45 (42.9%)	
Age	Mean (S.D.)	27.08 (2.89)	27.63 (4.72)	.377
Gender	Male	25 (64.1%)	72 (70.6%)	.457
	Not Male	14 (35.9%)	30 (29.4%)	
Race/ethnicity	White	24 (61.5%)	63 (61.8%)	.456
	Black	1 (2.6%)	8 (7.8%)	
	Hispanic	11 (28.2%)	28 (27.5%)	
	Mixed/Other	6 (4.3%)	3 (2.9%)	
Increased sterile				
syringe use	Yes	7 (17.5%)	17 (16.2%)	.850
	No	33 (82.5%)	88 (83.8%)	
Increased injection		·		
frequency	Yes	12 (30.0%)	36 (34.3%)	.624

	No	28 (70.0%)	69 (65.7%)	
People more likely to				
share syringes	Yes	16 (43.2%)	11 (12.5%)	<.001
	No	21 (56.8%)	77 (87.5%)	
Source for obtaining new syringes				
changed	Yes	16 (40.0%)	7 (6.7%)	<.001
	No	24 (60.0%)	98 (93.3%)	

<sup>t</sup>p-values are the results of Chi-square tests for categorial variables, Fisher exact tests for categorial
 variables with expected counts less than five, and independent sample t-tests for continuous variables.

- 307 Table 3 shows the results of a mixed effects logistic regression model with 308 random intercepts. Odds ratios and 95% confidence intervals based on cluster robust 309 standard error estimates are reported. Individuals in the post-vaccine phase had 310 significantly lower odds of reporting increased difficulty in accessing syringes (OR: 0.28: p=.003). Additionally, a changed source for obtaining new syringes resulted in 311 312 significantly higher odds of reporting increased difficulty in access syringes (OR: 7.49; 313 p<.0005). Perceiving people as more likely to share syringes also resulted in increased 314 odds of reporting increased difficulty in accessing syringes (OR: 2.29; p=.040). Gender, 315 age, and race/ethnicity did not significantly change the odds of reporting increased 316 difficulty in access syringes.
- 317

	318	Table 3: Results of Mixed Effect	ts Logistic Regression	Predicting Syringe Access
--	-----	----------------------------------	------------------------	---------------------------

	OR	95% Confidence Interval		p-value
Fixed Effects:				
Post-Vaccine Phase	0.28	0.12	0.65	.003
Source for obtaining new syringes changed	7.49	2.50	22.48	<.0005
People more likely to share syringes	2.29	1.04	5.05	.040
Male	0.60	0.28	1.27	.182
Age	0.97	0.90	1.05	.523

White	0.53	0.04	6.85	.624
Black	0.35	0.02	6.75	.487
Hispanic	0.39	0.03	5.84	.497
	Variance	Robust Std.	. Err.	
Random Effects:				
Intercept	.05	.69		

319

320

## 321 DISCUSSION

322 Our study examined changes in perceptions of access to harm reduction during the 323 COVID-19 pandemic among a sample of people who inject drugs in Chicago. Analyzing 324 baseline responses, we found that fewer participants during phase 2 of the COVID-19 325 pandemic in Chicago indicated difficulty in accessing syringes than in phase 1. This 326 finding was supported by mixed effects logistic regression results which showed 327 significantly decreased odds in reporting increased difficulty in accessing syringes 328 during the post-vaccine COVID-19 phase. Changing syringe sources and perceiving 329 individuals to be more likely to share syringes also resulted in increased odds of 330 reporting increased difficulty in accessing syringes. These findings indicated that, 331 among this sample of PWID, access to syringes was perceived as less difficult as the 332 pandemic progressed, and that individuals who reported changing syringe sources and 333 reported that people increased syringe sharing during the pandemic were also more 334 likely to report increased difficulty in accessing syringes.

The change in perceptions of access to syringes across COVID-19 phases can be interpreted through both changes to Chicago city policy as well as the policy changes at COIP (as described in the Introduction), which is a primary source of harm

338 reduction services for many study participants. The stay-at-home order that was in 339 effect from March, 2020 through the beginning of June, 2020 likely limited both study 340 participants' ability to access syringe exchange programs as well as programs' ability to 341 remain staffed and open (as evidenced by changes in COIP service provision). Existing 342 literature shows that many syringe exchange programs in other locations were quick to 343 adapt their programs through window, mobile, and telehealth services to minimize 344 interruptions to service. This was the case at COIP as well, where needle exchange 345 services were never stopped, and a window service had been established to continue to 346 provide syringes (19,20). In addition, as the pandemic progressed, COIP increased their mobile services. These quick policy adaptations at COIP could explain why most 347 348 participants did not perceive syringe access as changing during the pandemic. 349 Additionally, the stay-at-home order lifting and staff returning to COIP as well as mobile 350 services expanding could explain why more individuals in the beginning of the pandemic 351 reported difficulty in accessing syringes as opposed to later in the pandemic.

352 The results of this study align with the extant literature on harm reduction access 353 changes during the pandemic from the perspective of service providers. The present 354 study's results indicate that for most PWID in this sample, access to syringes and 355 Narcan did not become more difficult during the pandemic supporting the efficacy of 356 window and mobile syringe programs suggested by previous research. While it is 357 important that individuals did not perceive significant barriers to access to harm 358 reduction services, perceptions in access may not reflect the realities of engagement in 359 the services. Some studies have reported increases in overdose and risk behaviors 360 among PWID in Chicago during the pandemic, suggesting engagement in harm

reduction services may be lower as a result of the pandemic despite perceptions of 361 362 access not changing (5,23). Factors that influence risk taking behaviors and 363 engagement in harm reduction such as housing stability, mental health, and social 364 support worsened, which increased barriers to engagement in harm reduction services 365 resulting in poorer health outcomes for PWID (5). In the case of the present study, 366 individuals who responded to this survey were doing so as part of engagement in a 367 harm reduction service provider (COIP), meaning that these are individuals who were 368 able to receive these services and sought them out. While these individuals mostly 369 reported harm reduction access as remaining the same as prior to the pandemic, they 370 already had the ability to engage in these resources prior to seeking access. While 371 many PWID are able to access essential harm reduction services such as clean 372 syringes and Narcan, it is also essential to understand what barriers during the COVID-373 19 pandemic may have prevented PWID from engaging with these services. 374 Furthermore, while the results of this study indicate that adaptations to standard 375 SSP services through window service and mobile service are effective ways of providing harm reduction services to PWID in Chicago, this study did not examine the 376 377 impacts of the COVID-19 pandemic on participants' perceptions of access to other 378 services at COIP such as in-person counseling and HIV and HPV care. Prior studies 379 from the perspective of harm reduction providers have shown that these in-person 380 services were greatly reduced during COVID-19. Future research should consider how 381 the loss of these in-person services may have impacted PWID during the pandemic and 382 specifically how they may have impacted continued engagement in harm reduction 383 services.

384 *Limitations.* The current study is primarily limited by its sampling methods, which 385 reduces the generalizability of the results to populations outside of the sample of PWID 386 who participated in the study. Furthermore, this study recruited individuals and 387 administered surveys through a harm reduction service provider (COIP). This biases the 388 sample toward individuals who engaged in harm reduction services. Additionally, 389 measures in the study reflected participants' perceptions which means measurement 390 error may occur due to different interpretations of, for example, what it means for 391 something to be difficult or increase or decrease. Also, all survey questions were self-392 report, which creates the potential for response bias such as social desirability bias.

393

#### 394 CONCLUSION

The present study examined changes in PWID's perceptions of access to harm 395 396 reduction services in Chicago throughout the COVID-19 pandemic. Using data from an 397 ongoing longitudinal study of PWID in Chicago and a COVID-19 specific sub study we 398 analyzed participants' perceptions of access to syringes and Narcan across phases of 399 COVID-19 mitigation policies in Chicago as well as using mixed effects logistic 400 regression to explore predictors of perceived increased difficulty in syringe access. The 401 results of this analysis indicated that study participants perceived access to syringes 402 and Narcan to be similar as compared to prior to the pandemic, while more participants 403 found syringe access more difficult in the early part of the pandemic than later. These findings suggest that policy adaptations by COIP (the main harm reduction service 404 405 provider of study participants) allowed for minimal disruption in this sample of PWID's 406 access to syringes and Narcan. Further research is needed to understand the effects of

- 407 the pandemic on PWID's access to other essential harm reduction services such as
- 408 counseling and HIV/HPV testing as well as how the pandemic affected engagement by
- 409 PWID in all harm reduction services.
- 410
- 411
- 412
- 413 **REFERENCES**
- 414
- Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021 Jan;26(1):30–9.
- 418
  42. CDC. Centers for Disease Control and Prevention. 2020 [cited 2023 Aug 15].
  419 COVID-19 and Your Health. Available from: https://www.cdc.gov/coronavirus/2019420 ncov/need-extra-precautions/people-who-are-immunocompromised.html
- Vasylyeva TI, Smyrnov P, Strathdee S, Friedman SR. Challenges posed by COVID 19 to people who inject drugs and lessons from other outbreaks. Journal of the
   International AIDS Society. 2020;23(7):e25583.
- 42. Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug and Alcohol Dependence. 2007 May;88(2–3):188–96.
- 426 5. Aponte-Melendez Y, Mateu-Gelabert P, Fong C, Eckhardt B, Kapadia S, Marks K.
  427 The impact of COVID-19 on people who inject drugs in New York City: increased
  428 risk and decreased access to services. Harm Reduction Journal. 2021 Nov
  429 24;18(1):118.
- 430
  430
  431
  431
  432
  432
  433
  434
  435
  435
  436
  436
  436
  437
  437
  438
  438
  439
  439
  439
  430
  430
  430
  431
  431
  432
  433
  433
  434
  434
  435
  435
  436
  436
  437
  437
  438
  438
  439
  439
  439
  430
  430
  430
  430
  431
  431
  432
  433
  433
  434
  434
  435
  435
  436
  436
  437
  437
  438
  438
  438
  439
  439
  439
  430
  430
  430
  431
  431
  431
  432
  432
  433
  433
  434
  434
  435
  435
  436
  436
  437
  437
  438
  438
  438
  439
  439
  439
  430
  430
  431
  431
  432
  432
  433
  433
  434
  434
  435
  435
  436
  436
  437
  437
  438
  438
  438
  439
  439
  439
  430
  430
  430
  431
  431
  431
  432
  432
  432
  433
  433
  434
  434
  434
  435
  435
  436
  436
  437
  438
  438
  438
  439
  439
  439
  430
  430
  431
  431
  431
  432
  432
  433
  433
  434
  434
  434
  435
  435
  436
  436
  437
  438
  438
  438
  439
  439
- 434 7. Galea S, Vlahov D. Social determinants and the health of drug users:
  435 socioeconomic status, homelessness, and incarceration. Public Health Rep.
  436 2002;117(Suppl 1):S135–45.
- 437 8. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt
  438 Sinai J Med. 2000;67(5–6):423–8.
- 439
  439 S. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving Epidemiology of Hepatitis C
  440 Virus in the United States. Clin Infect Dis. 2012 Jul;55(Suppl 1):S3–9.

- 441 10. Paquette CE, Syvertsen JL, Pollini RA. Stigma at Every Turn: Health Services
  442 Experiences among People Who Inject Drugs. Int J Drug Policy. 2018 Jul;57:104–
  443 10.
- 444 11. Jemberie WB, Stewart Williams J, Eriksson M, Grönlund AS, Ng N, Blom Nilsson M,
  445 et al. Substance Use Disorders and COVID-19: Multi-Faceted Problems Which
  446 Require Multi-Pronged Solutions. Front Psychiatry. 2020 Jul 21;11:714.
- 447 12. Williams LD, Lee E, Latkin C, Mackesy-Amiti ME, Kaufmann M, Copulsky E, et al.
  448 Economic Challenges and Behavioral and Mental Health Risks for Overdose during
  449 the COVID-19 Pandemic among People Who Inject Drugs. Int J Environ Res Public
  450 Health. 2022 Apr 28;19(9):5351.
- 451 13. Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC.
  452 The Impact of COVID-19 on Syringe Services Programs in the United States. AIDS
  453 Behav. 2020;24(9):2466–8.
- 454 14. Abadie R, Gelpi-Acosta C, Aquino-Ruiz F, Aponte-Melendez Y. COVID-19 risks
  455 among people who inject drugs in Puerto Rico. Int J Drug Policy. 2021
  456 Jul;93:102903.
- 457 15. Puzhko S, Eisenberg MJ, Filion KB, Windle SB, Hébert-Losier A, Gore G, et al.
  458 Effectiveness of Interventions for Prevention of Common Infections Among Opioid
  459 Users: A Systematic Review of Systematic Reviews. Frontiers in public health.
  460 2022;10:749033–749033.
- 461 16. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Kazatchkine M, Sidibe M,
  462 Strathdee SA. Time to act: a call for comprehensive responses to HIV in people who
  463 use drugs. The Lancet. 2010 Aug 14;376(9740):551–63.
- 464 17. Pollack HA, Khoshnood K, Blankenship KM, Altice FL. The Impact of Needle
  465 Exchange–based Health Services on Emergency Department Use. J Gen Intern
  466 Med. 2002 May;17(5):341–8.
- 467 18. Vearrier L. The value of harm reduction for injection drug use: A clinical and public
  468 health ethics analysis. Disease-a-Month. 2019 May 1;65(5):119–41.
- 469 19. Austin EJ, Corcorran MA, Briggs ES, Frost MC, Behrends CN, Juarez AM, et al.
  470 Barriers to engaging people who use drugs in harm reduction services during the
  471 COVID-19 pandemic: A mixed methods study of syringe services program
  472 perspectives. International Journal of Drug Policy. 2022 Nov 1;109:103825.
- 20. Thakarar K, Kohut M, Hutchinson R, Bell R, Loeb HE, Burris D, et al. The impact of
  the COVID-19 pandemic on people who inject drugs accessing harm reduction
  services in an rural American state. Harm Reduct J. 2022 Jul 22;19:80.

- 476 21. Brener L, Horwitz R, Rance J, Caruana T, Bryant J. Health worker perceptions of
- the impact of COVID-19 on harm reduction services for people who inject drugs.
  Health & Social Care in the Community. 2022;30(6):2320–9.
- 479 22. Mackesy-Amiti ME, Falk J, Latkin C, Kaufmann M, Williams L, Boodram B.
- 480 Egocentric network characteristics of people who inject drugs in the Chicago metro 481 area and associations with hepatitis C virus and injection risk behavior. Harm 482 Boduction Journal 2022 Jun 2:10(1):58
- 482 Reduction Journal. 2022 Jun 2;19(1):58.
- 483 23. Friedman JR, Hansen H. Evaluation of Increases in Drug Overdose Mortality Rates
  484 in the US by Race and Ethnicity Before and During the COVID-19 Pandemic. JAMA
  485 Psychiatry. 2022 Apr 1;79(4):379–81.

		ALINH	
Phase 1	Phase 2	Phase 3	Phase 4
March 20, 2020 – June 2, 2020	June 3, 2020 – Dec. 31, 2020	Jan. 1, 2021 – Feb. 27, 2022	February 28, 2022
-Stay at home order	-Targeted restrictions (e.g., masks, limited gathering sizes, out of state travel limited)	-Vaccines become available - Vaccines required in public spaces	-"Phase IV" full reopening
Figure			